Demodex mites are microscopic parasites that live in the hair follicles and oil glands of human skin. Most adults carry them without knowing it. When their population grows beyond a clinical threshold, they cause a range of inflammatory conditions — many of which are misdiagnosed or go untreated for years. This guide explains what Demodex is, which conditions it causes, how it is diagnosed, and every treatment option currently available.
Demodex mites are obligate parasitic arachnids — meaning they can only survive on a host, specifically on mammals. In humans, they inhabit the pilosebaceous units of the face: the hair follicles, sebaceous glands, and meibomian glands of the eyelids. They feed on sebum (skin oil) and dead skin cells.
Demodex mites are the most common ectoparasite found on humans. Unlike many parasites that are picked up through environmental exposure, Demodex is transferred from person to person through close skin contact, most often from mother to infant during early life. By adulthood, the majority of people carry at least some mites.
At low densities, Demodex mites are generally considered commensals — living organisms that coexist with their host without causing harm. It is only when the mite population exceeds the skin’s ability to regulate it — typically defined as more than 5 mites per cm² in skin, or clinical signs of infestation on the eyelids — that disease results.
Two species of Demodex mites are specific to humans, and they occupy different anatomical locations with different clinical implications.
D. folliculorum is the larger of the two species, measuring approximately 0.3–0.4 mm in length. It lives primarily in the hair follicle itself, typically grouping in clusters of multiple mites within a single follicle. On the face, it is concentrated on the nose, cheeks, forehead, and chin. On the eyelids, it lives in the lash follicles and is the species most commonly associated with Demodex blepharitis.
The characteristic sign of D. folliculorum infestation on the eyelids is the presence of collarettes — waxy, cylindrical deposits at the base of the eyelashes composed of mite waste products and skin debris. Collarettes are considered pathognomonic for Demodex blepharitis, meaning their presence is essentially diagnostic.
D. brevis is smaller (approximately 0.15–0.2 mm) and lives deeper in the sebaceous and meibomian glands rather than in the follicle itself. Because of its deeper location, it is harder to detect by standard lash epilation and microscopy. D. brevis is thought to play a larger role in meibomian gland dysfunction (MGD) and posterior blepharitis than its follicular counterpart.
The prevalence of Demodex increases with age and varies with the diagnostic method used. The following figures are drawn from peer-reviewed studies and clinical data.
Despite the high prevalence, Demodex remains dramatically underdiagnosed. Of an estimated 25 million Americans with Demodex blepharitis, approximately 1.5 million have been formally diagnosed — roughly 6%. This diagnostic gap represents one of the largest unmet clinical needs in dermatology and ophthalmology today.
Multiple factors contribute to underdiagnosis: symptoms overlap with other conditions (dry eye, standard blepharitis, rosacea), definitive testing historically required lash epilation microscopy which is impractical in routine care, and awareness of demodex-related disease among clinicians — while growing — has historically been limited.
Understanding why Demodex populations can spiral is essential to understanding why treatment requires sustained effort rather than a single intervention.
The Demodex life cycle spans approximately 14–18 days and occurs entirely within the hair follicle or sebaceous gland. The cycle consists of five stages: egg, larva, protonymph, deutonymph, and adult. Mating occurs at the follicle opening, typically at night when mites are most active. Eggs are laid within the follicle and hatch within 3–4 days.
Each mite lives approximately 2–3 weeks. At low population densities, the immune system and normal skin cell turnover are sufficient to keep numbers in check. When this regulatory capacity is disrupted — by immune suppression, high sebum production, rosacea-related inflammation, or age-related skin changes — populations can grow rapidly.
Mites also carry bacteria on their surface, including Staphylococcus epidermidis and Bacillus oleronius. When mites die within the follicle (they have no excretory system and expel waste upon death), they release these bacteria along with proteases and lipases that trigger inflammatory cascades. This is one mechanism by which Demodex contributes to the chronic, relapsing nature of rosacea and blepharitis.
Demodex mites are implicated as a primary cause, contributing factor, or aggravator in a range of inflammatory conditions. The distinction matters clinically: in some conditions (blepharitis), Demodex is often the root cause; in others (rosacea), it is one of several interacting factors.
| Condition | Demodex’s role | Evidence strength |
|---|---|---|
| Demodex blepharitis | Direct cause. Mites in lash follicles produce collarettes, inflammation, and eyelid margin disease. Responsible for 58–69% of all blepharitis cases in US eye clinics. | Strong — FDA-approved treatment exists (Xdemvy, 2023) |
| Rosacea | Significant aggravating factor. Patients with rosacea have 9× the average Demodex density. Mites trigger inflammatory cascades; inflammation increases sebum production, which further feeds mites — a reinforcing cycle. | Strong — multiple meta-analyses including Chang & Huang, JAAD 2017 |
| Seborrheic dermatitis | Contributing factor. Elevated mite density is consistently found in seborrheic dermatitis, particularly affecting the face and scalp. Mites may amplify the inflammatory response to Malassezia yeast. | Moderate — association well documented; causality less established |
| Meibomian gland dysfunction (MGD) | D. brevis inhabits meibomian glands directly, disrupting lipid secretion and causing chronic dry eye symptoms. Tarsus Pharmaceuticals is currently evaluating Xdemvy for MGD in clinical trials. | Emerging — strong mechanistic basis; trial data pending |
| Perioral dermatitis | Elevated Demodex density is frequently observed. Treatment protocols targeting Demodex alongside standard therapy show improved outcomes in several case series. | Moderate — clinical correlation; limited RCT data |
| Folliculitis (Demodex folliculitis) | A specific subtype of folliculitis caused directly by Demodex overpopulation, presenting as pustular eruptions on the face. Often misdiagnosed as acne vulgaris. | Strong — direct causality; responds to anti-Demodex treatment |
Several factors are associated with higher Demodex mite density or increased susceptibility to Demodex-related disease:
Age. Infestation rates increase consistently with age — from roughly 25–30% in young adults to over 80% in those aged 60 and above, and approaching 100% in those over 70. This is thought to reflect age-related immune changes and cumulative mite exposure.
Rosacea. Patients with rosacea have 9 times the average Demodex infestation rate. The relationship is bidirectional — rosacea creates conditions favorable to mite proliferation, and mite proliferation worsens rosacea.
Diabetes mellitus. Multiple studies identify diabetes as a significant independent risk factor for Demodex infestation, likely due to immune dysregulation and altered sebum composition.
Immunosuppression. Patients on immunosuppressive therapy (including topical or systemic corticosteroids) show higher rates of clinically significant infestation. Misuse of topical steroids on the face is a recognized trigger for Demodex folliculitis.
Eyelash extensions and certain cosmetic practices. Mechanical disruption of lash follicles and the use of oily eye makeup create conditions favorable to mite colonization. Contact lens wear is also associated with higher rates of Demodex blepharitis in clinical studies.
Sex and sebum production. While overall infestation rates are equal between men and women, differences in facial sebum production — higher in men and in women with androgenic hormonal profiles — may influence mite density in affected areas.
Diagnosis depends on the condition being evaluated and the clinical setting. No single method is universally standard, but several reliable approaches exist.
For Demodex blepharitis, the most practical and clinically validated diagnostic sign is the presence of collarettes — cylindrical, waxy deposits encircling the base of the eyelashes. Collarettes are pathognomonic: a study by Gao et al. found that 100% of eyelashes with collarettes harbored Demodex mites, while only 7% without collarettes did.
Diagnosis by collarette identification requires only a standard slit-lamp examination. The patient is asked to look downward, exposing the upper lash margin. Collarettes are easily visible as clear to whitish cuffs at the base of the upper lashes. This simple observation can be incorporated into any routine eye exam.
For cutaneous demodicosis (affecting the face, not the eyes), the standard method is the standardized skin surface biopsy: a drop of cyanoacrylate adhesive is applied to the skin, covered with a glass slide, and removed after 1 minute. The material adhering to the slide is examined under light microscopy. A density of more than 5 mites per cm² is the accepted diagnostic threshold for clinically significant infestation.
Two to four eyelashes are epilated and examined under a light microscope. This is the gold-standard method for quantitative mite counts in clinical trials but is less practical in routine care due to patient discomfort and time requirements.
A non-invasive imaging technique that allows direct visualization of Demodex mites within the follicle or gland. Available in specialist centers; not routine in primary care settings.
Treatment options vary by site (eyelids vs. skin) and severity. The following represents the current evidence-based landscape. This site does not endorse any specific brand.
You should consult a dermatologist or ophthalmologist if you experience any of the following:
On the eyelids or eyes: persistent itching, burning, or foreign body sensation in the eyes, particularly if worst in the morning; visible crusting or waxy deposits at the base of the eyelashes; eyelash loss, misdirected lashes, or recurrent styes; chronic dry eye that does not respond to standard lubricating drops.
On the skin: chronic redness, papules, or pustules on the central face (nose, cheeks, forehead, chin) that have not responded to standard acne or rosacea treatments; itching or burning of facial skin, particularly around the nose and cheeks; skin symptoms that worsen after applying topical corticosteroids.
If you are unsure whether your symptoms are Demodex-related, use our symptom checker or find a physician experienced with demodicosis near you.
Most adults carry some Demodex mites. Infestation rates increase with age, reaching over 80% in adults over 60 and approaching 100% in those over 70. At low densities, mites are typically harmless. Problems arise when the population grows beyond the clinical threshold due to immune changes, hormonal factors, skin conditions, or other triggers.
Yes, though transmission requires close contact. Demodex mites are primarily transferred from caregiver to infant during early childhood through skin-to-skin contact. Person-to-person transmission in adulthood through normal social contact is possible but limited, as mites survive only briefly outside the follicle environment. Sharing towels, pillowcases, or eye makeup applicators with an affected person presents the most practical transmission risk.
Demodex mites in scalp follicles have been associated with seborrheic dermatitis and folliculitis, both of which can contribute to hair loss if untreated and sustained. However, Demodex is not a primary cause of androgenic alopecia or most other hair loss conditions. Eyelash loss (madarosis) is a recognized complication of severe Demodex blepharitis.
No. At 0.15–0.4 mm in length, Demodex mites are too small to see without magnification. They can be visualized using light microscopy (after lash epilation or skin surface biopsy) or in vivo confocal microscopy in clinical settings.
Subclinical Demodex (mite populations below the clinical threshold) naturally fluctuates and does not require treatment. Clinical demodicosis — where mite density has exceeded the threshold and is causing active disease — generally does not resolve without targeted treatment. The chronic, relapsing nature of conditions like rosacea and blepharitis often reflects persistent Demodex activity that is not self-limiting.
Current treatments reduce mite populations to subclinical levels; they do not permanently eradicate Demodex from the skin. Mite populations may rise again after treatment ends, which is why maintenance protocols — sustained hygiene practices and periodic topical use — are recommended after initial treatment courses.
